VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LGND
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LGNDLigand Pharmaceuticals Incorporated
$293.81$6.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLGNDCash Flow

Ligand Pharmaceuticals Incorporated (LGND) Cash Flow Statement

30Y historyFree accessUpdated daily

Operating cash flow of $48.7M in Q1 2026 reversed to -$27.6M in Q3 2026 with free cash flow at -$27.7M, while a $836.3M net acquisition outflow and $60.0M in buybacks signal capital deployment outpacing recent cash generation.

Income StatementBalance SheetCash FlowRatios

LGND Cash Flow Statement

Annual statement

LGND Cash Flow Statement

Ligand Pharmaceuticals Incorporated (LGND) cash flow statement — 30-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations90.96M49.36M97.05M49.58M137.85M78.8M54.59M-29.34M194.06M93.57M63M41.73M20.57M20.69M161K-1.17M-27.07M-33.8M-20.63M-97.73M-138.52M8.37M5.75M274K-25.11M-19.91M-47.35M-60.5M-66.6M-13.4M-33.3M
Operating CF Margin %-18.41%58.07%37.75%70.24%32.62%33.37%-24.39%77.18%66.31%57.81%58.02%31.87%42.25%0.51%-3.9%-114.99%-86.8%-75.51%-757.93%-98.27%4.74%3.52%0.19%-25.99%-26.08%-98.43%-147.92%-376.27%-25.92%-90.49%
Operating CF Growth %93.11%-49.14%95.75%-64.04%74.94%44.36%286.07%-115.12%107.4%48.52%50.98%102.89%-0.6%12750.93%113.74%95.67%19.92%-63.88%78.9%29.45%-1755.96%45.38%2000%101.09%-26.15%57.96%21.73%9.16%-397.01%59.76%12.14%
Net Income51.46M124.45M-4.03M52.15M-33.36M57.14M-2.98M629.3M143.32M12.56M-2.37M254.93M10.89M8.83M-2.67M10.17M-12.79M-8.34M-98.11M281.69M-31.74M-36.4M-45.14M-37.46M-32.6M-42.99M-59.28M-74.7M-117.9M-100.2M-37.3M
Depreciation & Amortization36.38M33.77M35.24M36.52M43.39M50.95M27.97M43.73M14.72M11.71M11.29M2.63M2.66M2.66M2.73M2.79M2.21M3.13M1.05M2.62M16.22M18.71M15.28M14.28M10.47M6.57M6.97M7.4M7.7M9.8M9.4M
Stock-Based Compensation56.7M041.09M25.74M60.28M38.78M30.73M24.52M20.85M24.91M18.89M12.46M11.27M5.67M4.07M3.35M2.33M3.37M-537K7.58M5.34M107K000000000
Deferred Taxes-8.35M22.68M-15.8M11.7M20.72M-8.62M-19.05M74.83M29.74M44.52M10.7M-219.61M410K374K-1.2M-13.26M5.99M-22.8M-1.36M-5.79M-9.66M-107K000000000
Other Non-Cash Items-5.82M-118.89M21.2M-42.13M-18.87M-7.29M28M-797.5M24.29M11.3M35.11M-9.49M6.29M3.86M13K1.65M-68K9.17M79.64M-327.99M-36.01M-578K-5.57M8.59M3.83M16.56M-2.79M15.5M45.1M64.9M-1.4M
Working Capital Changes-39.41M-12.66M19.36M-34.4M65.68M-52.16M-10.06M-4.21M-38.85M-11.44M-10.62M821K-10.95M-702K-2.77M-5.88M-24.74M-18.33M-1.31M-55.83M-82.66M26.64M41.19M14.86M-6.81M-42K7.74M-8.7M-1.5M12.1M-4M
Change in Receivables-25.8M-21.74M-6.46M-2.6M55.32M-28.62M-26.06M25.46M-29.54M-8.36M-8.53M6.49M-10.41M2.37M1.52M-3.92M-375K-618K011.54M9.43M0-11.95M-6.88M0000000
Change in Inventory-2.61M4.99M9.62M-10.87M12.06M-427K-17.8M-2.06M-2.56M-843K-244K-401K4.37M646K1.03M1.11M-3.93M-448K0930K1.58M-3.43M-3.29M-3.42M-1.08M1.9M81K400K-2.9M00
Change in Payables8.91M5.88M0-4.7M-3.34M-1.17M-1.25M-18.05M-4.54M-1.71M-2.37M-4.03M-3.15M-2.76M-4.8M-11.57M-13.45M-10.99M0-51.89M-27.64M09.75M24.52M0000000
Cash from Investing-669.33M-377.32M-143.66M-11.68M163.62M30.52M231.65M466.92M-423.27M-84.18M-143.19M-112.86M-2.03M-4.97M1.26M-25.13M14.54M24.77M-24.42M343.84M196.87M-33.72M19.61M-24.62M-105.25M-4.17M14.65M-24.9M-28.6M4.3M7.5M
Capital Expenditures-3.04M-11.31M-1.82M-3.52M-17.92M-8.76M-4.46M-2.55M-11.89M-7.15M-28.32M-10.86M-4.5M-4.94M-8.64M-78K-70K-522K-495K-440K-1.78M-35.6M-3.6M-2.78M-3.16M-1.97M-1.08M-39.5M-2.4M-4.3M-400K
CapEx % of Revenue1.2%4.22%1.09%2.68%9.13%3.63%2.73%2.12%4.73%5.07%25.99%15.11%6.97%10.08%27.54%0.26%0.3%1.34%1.81%3.41%1.26%20.16%2.2%1.97%3.27%2.59%2.26%96.58%13.56%8.32%1.09%
Acquisitions-836.33M-8.09M-172.19M-25.65M-750K494K-383.32M-12.84M-5.86M-26.65M-94.2M-9.25M-3.49M-989K0-32.02M-2.83M9.8M4.13M310.14M183.33M00000-200K0100K100K0
Investments-------------------------------
Other Investing9.88M-4.34M-12.89M-49.91M-868K-1.22M3.26M808.13M3.91M7.25M300K-15.99M130K-37K-93K-2.38M-1.01M539K8.29M39.59M8.14M181K-131K-3.86M-106.2M281K11.88M-5.2M-9.3M-16.8M-200K
Cash from Financing544.69M428.22M97.14M-59.95M-275.99M-137.76M-310.55M-485.17M328.58M-7.52M1.51M8.36M130.03M-16.46M3.92M30M-159K-3.69M-3.01M-327.7M33.3M-201K7.92M40.95M152.04M35.59M12.03M82.5M65.8M36.5M44.7M
Debt Issued (Net)488.78M338.11M-25K-76.9M-260.8M-146.01M-231.76M-27.32M532.33M000235.63M-19.59M-2.5M30M-91K-3.92M-1.53M-2.17M24.4M-1.1M1.49M-1.35M99.38M7.96M-2.75M59.6M27M-700K2.4M
Equity Issued (Net)85.28M99.89M37.14M22.45M3.23M15.32M-78M-457.47M-126.63M-1.97M2.51M-489K-67.95M3.13M5.44M-55K-68K228K-1.48M-35.22M9.05M930K6.62M33.58M70.75M28.58M14.19M22.3M38.3M36.7M39M
Dividends Paid0000000000000000000-252.56M00000000000
Share Repurchases-60M-15M000-18.45M-78M-453.05M-122.87M-1.97M-3.9M-489K-67.95M00-55K-91K0-1.61M-39.61M000-15.87M0000000
Other Financing-29.36M-9.77M60.03M-5.5M-18.42M-7.07M-789K-383K-77.11M-5.56M-999K8.85M-37.66M0979K54K000-37.56M-153K-35K-189K8.72M-18.09M-936K577K600K500K500K3.3M
Net Change in Cash-35.98M102.62M49.35M-22.05M25.48M-28.44M-24.31M-47.51M99.16M1.87M-78.68M-62.77M148.56M-742K5.34M3.69M-12.69M-12.72M-48.06M-81.59M91.64M-25.55M33.28M16.61M21.68M11.52M-20.68M-2.9M-29.5M27.4M18.9M
Free Cash Flow90.56M48.91M77.41M-4.27M119.93M70.04M50.13M-31.89M182.17M86.41M34.68M30.86M16.07M15.75M-8.48M-1.25M-27.14M-34.32M-21.12M-98.17M-140.3M-27.23M2.15M-2.51M-28.27M-21.88M-48.44M-100M-69M-17.7M-33.7M
FCF Margin %35.68%18.24%46.31%-3.25%61.11%29%30.65%-26.51%72.45%61.24%31.82%42.92%24.9%32.17%-27.03%-4.16%-115.29%-88.14%-77.32%-761.34%-99.53%-15.42%1.31%-1.78%-29.26%-28.66%-100.69%-244.5%-389.83%-34.24%-91.58%
FCF Growth %195.1%-36.82%1911.96%-103.56%71.23%39.72%257.2%-117.5%110.81%149.18%12.36%92.1%1.99%285.7%-578.64%95.39%20.94%-62.51%78.49%30.03%-415.24%-1366.56%185.69%91.13%-29.22%54.83%51.56%-44.93%-289.83%47.48%11.55%
FCF per Share4.542.414.23-0.247.114.063.10-1.617.573.681.661.450.750.76-0.43-0.06-1.38-1.82-1.33-6.00-10.44-2.210.18-0.21-2.45-2.21-5.22-12.73-10.25-3.21-7.03
FCF Conversion (FCF/Net Income)1.76x0.40x-24.07x0.95x-4.13x1.38x-18.29x-0.05x1.35x7.45x-38.51x0.16x1.71x1.81x-0.31x-0.12x2.16x17.35x0.21x-0.35x4.36x-0.23x-0.13x-0.01x0.77x0.46x0.65x0.81x0.56x0.13x0.89x
Interest Paid2.34M0263K288K1.43M3.03M4.46M5.83M1.51M1.84M1.84M1.82M494K1.82M02.46M58K270K229K1.51M00000000000
Taxes Paid4.67M019.21M8.77M11.64M3.72M2.13M103.82M341K157K38K28K18K26K039K28K14K140K8.37M00000000000

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Volatile operating cash conversion

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Net Income Poorly Converts to Operating Cash

Based on reported quarterly figures, LGND's operating cash flow to net income ratio swung from -3.65 in Q1 2026 to 3.26 in Q2 2025, indicating earnings quality that is highly unstable and not reliably backed by cash generation.

The ratio gyrates between negative and strongly positive values, largely because net income is distorted by non-operating items and lumpy milestone or royalty recognition, as the Q3 2025 net income of $117.3M against operating cash flow of just $13.1M illustrates. This pattern suggests reported profitability should be treated with caution until cash conversion stabilizes across several consecutive quarters. Investors should monitor whether operating cash flow catches up to earnings over a longer window.

Free Cash Flow Turns Negative Recently

Per reported figures, LGND's free cash flow margin moved from 93.7% in Q1 2026 to -35.2% in Q3 2026, with free cash flow of -$27.7M in the most recent quarter after a $48.5M result in the prior quarter.

The swing reflects the volatility of royalty timing and working capital movements rather than a steady underlying cash trajectory, with working capital changes of -$47.6M in Q3 2026 weighing heavily on the period. Because capital expenditure is minimal, the free cash flow profile is driven almost entirely by operating cash timing, making single-quarter readings poor indicators of run-rate. Management's ability to sustain positive free cash flow across quarters warrants further investigation.

Cash Deployed Toward Acquisitions and Buybacks

As reported in the financial statements, LGND recorded a net acquisition outflow of $836.3M in Q3 2026 and share repurchases of $60.0M in Q2 2026, while paying no dividends across the period.

The scale of the Q3 2026 acquisition outflow relative to quarterly operating cash flow indicates the company is funding growth through balance sheet capacity rather than internally generated cash. The absence of dividends alongside repurchases suggests capital is being prioritized for royalty acquisitions and selective buybacks. Investors should assess whether acquired royalty streams generate returns sufficient to justify the deployed capital, given the reported cash volatility.

Stock Compensation Masks Cash Cost

Based on the supplied data, stock-based compensation of $18.2M in Q3 2026 and $13.7M in Q2 2026 represents a non-cash add-back that flatters operating cash flow while still diluting shareholders.

Because stock-based compensation is added back to arrive at operating cash flow, the reported cash generation overstates the economic cost of running the platform, relative to the quarterly operating income of $8.6M in Q2 2026. This implies that the true cash-equivalent earnings power may be lower than headline cash flow suggests. Investors may wish to evaluate free cash flow after treating equity compensation as a real expense.

LGND — Frequently Asked Questions

Quick answers to the most common questions about buying LGND stock.

How much cash does Ligand Pharmaceuticals Incorporated (LGND) generate from operations?

Ligand Pharmaceuticals Incorporated (LGND) generated $49.4M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Ligand Pharmaceuticals Incorporated's free cash flow?

Ligand Pharmaceuticals Incorporated (LGND) generated $48.9M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Ligand Pharmaceuticals Incorporated's capital expenditure (CapEx)?

Ligand Pharmaceuticals Incorporated (LGND) spent $11.3M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Ligand Pharmaceuticals Incorporated distribute cash to shareholders?

In 2025, Ligand Pharmaceuticals Incorporated (LGND) spent $15.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.